https://news.medxy.ai/zh/biological-age-predicts-brain-disease/Medxy AIzh2026-04-14T10:19:42-07:00生物年龄在预测脑小血管病进展方面超越了实际年龄 https://news.medxy.ai/ja/biological-age-predicts-cerebral-vascular-disease/Medxy AIja2026-04-14T10:18:28-07:00生物学年齢が脳小血管病の進行を予測する https://news.medxy.ai/vi/biological-age-predicts-stroke/Medxy AIvi2026-04-14T10:16:04-07:00Tuổi Sinh Học Nhanh Hơn Tuổi Thực Trong Dự Đoán Tiến Trình Bệnh Mạch Máu Não Nhỏ https://news.medxy.ai/biological-age-predicts-disease/Medxy AIen2026-04-14T10:11:53-07:00Biological Age Outpaces Chronological Age in Predicting Cerebral Small Vessel Disease Progression https://news.medxy.ai/zh/women-and-alzheimers-research/Medxy AIzh2026-04-13T23:48:49-07:00为何女性表现出更高的淀粉样蛋白负担：关于性别、种族和APOE ε4在阿尔茨海默病病理中的相互作用的新证据 https://news.medxy.ai/ja/women-alzheimer-protein-burden/Medxy AIja2026-04-13T23:46:24-07:00女性为何表现出更高的淀粉样蛋白负担：阿尔茨海默病病理中性别、种族和APOE ε4相互作用的新证据 https://news.medxy.ai/vi/women-amd-amyloid-burden/Medxy AIvi2026-04-13T23:44:03-07:00Tại sao Phụ nữ Có Gánh Nặng Amyloid Cao hơn: Bằng chứng Mới về Tương tác Giới, Dân tộc và APOE ε4 trong Bệnh lý Alzheimer https://news.medxy.ai/women-amyloid-burden/Medxy AIen2026-04-13T23:39:39-07:00Why Women Show Higher Amyloid Burden: New Evidence on Sex, Race, and APOE ε4 Interactions in Alzheimer’s Pathology https://news.medxy.ai/zh/three-modifiable-predictors-thyroid-cancer/Medxy AIzh2026-04-13T19:38:02-07:00甲状腺癌患者情感障碍的三个可改变预测因素：临床医生需要了解的内容 https://news.medxy.ai/ja/thyroid-cancer-emotional-factors/Medxy AIja2026-04-13T19:36:25-07:00甲状腺癌患者的情感障碍可由三个可改变因素预测：临床医生需要了解的内容 https://news.medxy.ai/vi/factors-changing-emotional-disorder-prediction/Medxy AIvi2026-04-13T19:34:32-07:00Ba yếu tố có thể thay đổi dự đoán rối loạn cảm xúc ở bệnh nhân ung thư tuyến giáp: Điều mà các bác sĩ cần biết https://news.medxy.ai/modifiable-factors-thyroid-cancer/Medxy AIen2026-04-13T19:30:48-07:00Three Modifiable Factors Predict Emotional Impairment in Thyroid Cancer Patients: What Clinicians Need to Know https://news.medxy.ai/zh/wbc-spect-ct-diabetes-foot-infection/Medxy AIzh2026-04-13T18:39:14-07:00研究发现：WBC SPECT/CT 在糖尿病足骨髓炎早期诊断中优于 MRI https://news.medxy.ai/ja/wbc-spect-ct-mri-diabetes/Medxy AIja2026-04-13T18:37:55-07:00WBC SPECT/CTがMRIを上回り、糖尿病性足部骨髄炎の早期診断で優れた性能を示す – 研究結果 https://news.medxy.ai/vi/wbc-spect-ct-vs-mri-diabetic-foot/Medxy AIvi2026-04-13T18:36:05-07:00Nghiên cứu cho thấy WBC SPECT/CT vượt trội hơn MRI trong việc phát hiện sớm xương chày do chân bị tiểu đường https://news.medxy.ai/wbc-spect-ct-vs-mri/Medxy AIen2026-04-13T18:32:35-07:00WBC SPECT/CT Outperforms MRI in Early Detection of Diabetic Foot Osteomyelitis, Study Finds https://news.medxy.ai/zh/primary-hyperparathyroidism-increase/Medxy AIzh2026-04-13T16:34:52-07:00原发性甲状旁腺功能亢进症发病率和患病率显著增加：斯德哥尔摩15年研究 https://news.medxy.ai/ja/hyperthyroidism-increase-study/Medxy AIja2026-04-13T16:33:24-07:00主甲状腺機能亢進症の増加傾向：ストックホルム研究が15年間の発症率と有病率の著しい増加を明らかにする https://news.medxy.ai/vi/primary-hyperthyroidism-trends/Medxy AIvi2026-04-13T16:31:26-07:00Dòng thủy triều tăng của bệnh cường giáp trạng nguyên phát: Nghiên cứu Stockholm tiết lộ sự gia tăng đáng kể về tỷ lệ mắc mới và phổ biến trong 15 năm https://news.medxy.ai/rising-primary-hyperparathyroidism/Medxy AIen2026-04-13T16:28:16-07:00Rising Tide of Primary Hyperparathyroidism: Stockholm Study Reveals Dramatic Increase in Incidence and Prevalence Over 15 Years https://news.medxy.ai/zh/surgical-metabolic-intervention/Medxy AIzh2026-04-13T15:55:36-07:00外科代谢干预：减肥手术在1型糖尿病合并肥胖患者中的效果 https://news.medxy.ai/ja/surgery-metabolic-intervention/Medxy AIja2026-04-13T15:54:10-07:00手術代謝介入：減重手術改變肥胖型1型糖尿病患者的預後 https://news.medxy.ai/vi/metabolic-surgery-diabetes-type-1/Medxy AIvi2026-04-13T15:52:28-07:00Can thiệp phẫu thuật chuyển hóa: Phẫu thuật giảm cân biến đổi kết quả trong đái tháo đường tuýp 1 có béo phì https://news.medxy.ai/bariatric-surgery-type1-diabetes/Medxy AIen2026-04-13T15:47:03-07:00Surgical Metabolic Intervention: Bariatric Surgery Transforms Outcomes in Type 1 Diabetes With Obesity https://news.medxy.ai/zh/mavacamten-obstructive-hypertrophic-cardiomyopathy/Medxy AIzh2026-04-13T15:02:31-07:00Mavacamten通过逆转Anrep反应在梗阻性肥厚型心肌病中实现手术级别的血流动力学纠正 https://news.medxy.ai/ja/mavakamten-anrep-reversal/Medxy AIja2026-04-13T15:01:27-07:00マバカムテンはAnrep反応を逆転させることで肥厚型心筋症の手術的な血行動態補正を達成 https://news.medxy.ai/vi/mavacamten-huyet-dong/Medxy AIvi2026-04-13T15:00:04-07:00Mavacamten đạt hiệu chỉnh huyết động tương đương phẫu thuật trong bệnh cơ tim dày cản trở bằng cách đảo ngược phản ứng Anrep https://news.medxy.ai/mavacamten-hemodynamic-correction/Medxy AIen2026-04-13T14:56:27-07:00Mavacamten Achieves Surgical-Grade Hemodynamic Correction in Obstructive Hypertrophic Cardiomyopathy by Reversing the Anrep Response https://news.medxy.ai/zh/tuxedo-2-trial-platelet-selection/Medxy AIzh2026-04-13T13:55:05-07:00替格瑞洛未能达标：TUXEDO-2试验挑战糖尿病多支病变患者的抗血小板选择 https://news.medxy.ai/ja/tuxedo-2-trial-platelet-drugs/Medxy AIja2026-04-13T13:53:26-07:00チカグレロールは不十分：TUXEDO-2試験が糖尿病患者における抗血小板薬選択に挑戦 https://news.medxy.ai/vi/ticagrelor-fails-tuxedo-2/Medxy AIvi2026-04-13T13:50:38-07:00Ticagrelor Không Đạt Mục Tiêu: Thử Nghiệm TUXEDO-2 Thách Thức Lựa Chọn Chống Huyết T板 https://news.medxy.ai/ticagrelor-tuxedo-2-trial/Medxy AIen2026-04-13T13:47:16-07:00Ticagrelor Falls Short: TUXEDO-2 Trial Challenges Antiplatelet Choice in Diabetic Patients With Multivessel Disease https://news.medxy.ai/zh/why-measuring-exercise-blood-pressure-misses-cardiovascular-risk/Medxy AIzh2026-04-13T13:24:00-07:00为什么单独测量运动血压可能错过心血管风险——与体能结合后揭示了什么 https://news.medxy.ai/ja/exercise-blood-pressure-risk/Medxy AIja2026-04-13T13:22:47-07:00運動血圧のみでは心血管リスクを見逃す可能性がある—フィットネスとの組み合わせが明らかにするもの https://news.medxy.ai/vi/blood-pressure-and-fitness/Medxy AIvi2026-04-13T13:21:06-07:00Tại sao chỉ đo huyết áp trong tập luyện có thể bỏ sót rủi ro tim mạch – và việc kết hợp nó với sức khỏe thể chất tiết lộ điều gì https://news.medxy.ai/exercise-blood-pressure-risk/Medxy AIen2026-04-13T13:17:34-07:00Why Exercise Blood Pressure Alone May Miss Cardiovascular Risk—and What Combining It With Fitness Reveals https://news.medxy.ai/quality-of-life-ctos/Medxy AIen2026-04-13T13:14:26-07:00Quality of Life After Percutaneous Coronary Intervention or Medical Therapy for Chronic Total Coronary Occlusions: EUROCTO and DECISION-CTO Meta-Analysis https://news.medxy.ai/zh/mobile-health-intervention/Medxy AIzh2026-04-13T12:58:39-07:00移动健康干预使加纳中风幸存者血压控制率提高24%：PINGS试验结果 https://news.medxy.ai/ja/mobile-health-intervention-stroke/Medxy AIja2026-04-13T12:57:19-07:00モバイルヘルス介入が脳卒中生存者の血圧管理を24%向上させる：ガーナのPINGS試験結果 https://news.medxy.ai/vi/mobile-health-intervention-better-blood-pressure/Medxy AIvi2026-04-13T12:55:34-07:00Can thiệp Sức khỏe Di động Đạt được Kiểm soát Huyết áp Tốt hơn 24% ở Người sống sót sau Đột quỵ: Kết quả Thử nghiệm PINGS từ Ghana https://news.medxy.ai/zh/nsclc-survivors-pembrolizumab/Medxy AIzh2026-04-13T12:54:04-07:00接受帕博利珠单抗治疗的非小细胞肺癌长期生存者显示高生存率，罕见免疫治疗再挑战 https://news.medxy.ai/mobile-health-intervention-blood-pressure/Medxy AIen2026-04-13T12:52:29-07:00Mobile Health Intervention Achieves 24% Better Blood Pressure Control in Stroke Survivors: PINGS Trial Results from Ghana https://news.medxy.ai/ja/pemprolizumab-nsclc-survivors/Medxy AIja2026-04-13T12:52:18-07:00ペムブロリズマブ後の長期非小細胞肺がん生存者、高い生存率と稀な免疫療法再挑戦 https://news.medxy.ai/vi/long-term-survivors-nsclc-pembrolizumab/Medxy AIvi2026-04-13T12:49:52-07:00Những Người Sống Sót Dài Hạn với NSCLC Sau Khi Sử Dụng Pembrolizumab Có Tỷ Lệ Sống Cao và Hiếm Khi Cần Phải Tiếp Tục Điều Trị Miễn Dịch https://news.medxy.ai/long-term-nsclc-survivors/Medxy AIen2026-04-13T12:45:34-07:00Long-Term NSCLC Survivors After Pembrolizumab Show High Survival Rates, Rare Immunotherapy Rechallenge https://news.medxy.ai/zh/swedish-study-semaglutide-hope/Medxy AIzh2026-04-13T12:37:57-07:00瑞典研究发现：司美格鲁肽在减少抑郁症和焦虑症患者精神疾病恶化方面显示出希望 https://news.medxy.ai/ja/semaglutide-mental-health-study/Medxy AIja2026-04-13T12:36:44-07:00セマグルチド、うつ病と不安症の患者の精神障害悪化を軽減する可能性 – スウェーデンの研究 https://news.medxy.ai/vi/semaglutide-depression-anxiety/Medxy AIvi2026-04-13T12:35:08-07:00Semaglutide Hiển Thị Tiềm Năng Giảm Nguy Cơ Tệ Hóa Bệnh Tâm Thức ở Người Bị Trầm Cảm và Lo Âu, Nghiên Cứu Thụy Điển https://news.medxy.ai/semaglutide-mental-health/Medxy AIen2026-04-13T12:31:53-07:00Semaglutide Shows Promise in Reducing Mental Illness Worsening in Patients with Depression and Anxiety, Swedish Study Finds https://news.medxy.ai/zh/machine-learning-mindfulness-youth-depression/Medxy AIzh2026-04-13T11:36:07-07:00机器学习在个性化学校正念训练预防青少年抑郁症中的不足：MYRIAD试验见解 https://news.medxy.ai/ja/machine-learning-mindfulness-impact/Medxy AIja2026-04-13T11:34:53-07:00機械学習が学校でのマインドフルネスを個別化するうえで若年期うつ病予防に及ぼす影響の限界：MYRIAD試験の洞察 https://news.medxy.ai/vi/machine-learning-personalization-depression/Medxy AIvi2026-04-13T11:33:09-07:00Học Máy Không Đủ Hiệu Quả trong Cá Nhân Hóa Đào Tạo Tỉnh Thức tại Trường Học để Phòng Ngừa Trầm Cảm ở Thanh Thiếu Niên: Những Nhận Xét từ Thử Nghiệm MYRIAD https://news.medxy.ai/machine-learning-mindfulness-adolescents/Medxy AIen2026-04-13T11:30:37-07:00Machine Learning Falls Short in Personalizing School-Based Mindfulness for Adolescent Depression Prevention: MYRIAD Trial Insights https://news.medxy.ai/zh/bromosonazole-ic-sedation/Medxy AIzh2026-04-13T11:29:08-07:00苯磺酸瑞马唑仑在短期ICU镇静中与丙泊酚相当：SHOSREB试验 https://news.medxy.ai/ja/remimazolam-equivalence-icu-sedation/Medxy AIja2026-04-13T11:27:02-07:00レミマゾラムベシレート、プロポフォールと同等の短期ICU鎮静効果：SHOSREB試験 https://news.medxy.ai/vi/remimazolam-propofol-icuthreshold/Medxy AIvi2026-04-13T11:25:00-07:00Remimazolam Besylate phù hợp với Propofol cho gây mê ngắn hạn ở bệnh nhân ICU: Thử nghiệm SHOSREB https://news.medxy.ai/remimazolam-vs-propofol-icu-sedation/Medxy AIen2026-04-13T11:22:04-07:00Remimazolam Besylate Matches Propofol for Short-Term ICU Sedation: The SHOSREB Trial https://news.medxy.ai/zh/real-patient-counts/Medxy AIzh2026-04-13T11:20:57-07:00如何通过急救医疗服务数据中的匹配算法揭示真实患者数量 https://news.medxy.ai/ja/real-patient-count-algorithm/Medxy AIja2026-04-13T11:19:41-07:00救急医療サービスデータから真の患者数を明らかにするマッチングアルゴリズム https://news.medxy.ai/vi/dual-algorithms-patient-count/Medxy AIvi2026-04-13T11:17:46-07:00Cách Các Thuật Toán Phối Đôi Có Thể Phát Hiện Số Lượng Bệnh Nhân Thực Sự Từ Dữ Liệu Dịch Vụ Y Tế Khẩn Cấp https://news.medxy.ai/matching-algorithms-patient-counts/Medxy AIen2026-04-13T11:14:08-07:00How Matching Algorithms Can Uncover True Patient Counts From Emergency Medical Services Data https://news.medxy.ai/unforgiving-academia/Medxy AIen2026-04-13T11:10:24-07:00Academia Is a Very Unforgiving Space: A Qualitative Study of Challenges Faced by Under-represented Scholars in Biomedical Research https://news.medxy.ai/zh/daily-umekridine-vilanterol-copd/Medxy AIzh2026-04-13T10:37:12-07:00每日一次乌美克利丁-维兰特罗在减少COPD急性加重方面优于其他LAMA-LABA组合 https://news.medxy.ai/ja/umeclidinium-bila-terol-copd/Medxy AIja2026-04-13T10:35:52-07:001日に1回のウメクリジニウム・ビルアンテロールが他のLAMA-LABA併用療法よりもCOPD急性増悪を抑制 https://news.medxy.ai/vi/umeclidinium-vilanterol-copd-2/Medxy AIvi2026-04-13T10:34:13-07:00Umeclidinium-Vilanterol Một Lần Một Ngày Hiệu Quả Hơn Các Kết Hợp LAMA-LABA Khác Trong Việc Giảm Tần Suất Tái Phát COPD https://news.medxy.ai/umeclidinium-vilanterol-copd/Medxy AIen2026-04-13T10:31:25-07:00Once-Daily Umeclidinium-Vilanterol Outperforms Other LAMA-LABA Combinations in Reducing COPD Exacerbations https://news.medxy.ai/zh/effectiveness-of-antihypertensives-2/Medxy AIzh2026-04-13T10:28:53-07:00降压药物治疗孤立性舒张期高血压的有效性：证据的系统综合 https://news.medxy.ai/ja/effectiveness-of-antihypertensives/Medxy AIja2026-04-13T10:27:31-07:00単独収縮期高血圧における降圧薬の有効性：エビデンスの体系的な統合 https://news.medxy.ai/vi/effectiveness-of-blood-pressure-therapy/Medxy AIvi2026-04-13T10:25:43-07:00Hiệu quả của liệu pháp giảm huyết áp trong tăng huyết áp tâm trương đơn độc: Tổng hợp bằng chứng có hệ thống https://news.medxy.ai/blood-pressure-therapy-diabetes/Medxy AIen2026-04-13T10:22:06-07:00Efficacy of Blood Pressure-Lowering Pharmacotherapy in Isolated Diastolic Hypertension: A Systematic Synthesis of Evidence https://news.medxy.ai/zh/tp53-mutations-cd19-car-t/Medxy AIzh2026-04-12T23:11:39-07:00TP53 突变在 CD19-CAR T 细胞治疗复发/难治性 B-ALL 的儿科和年轻成人患者中成为关键不良预后因素 https://news.medxy.ai/ja/tp53-abnormality-b-adult-cancer/Medxy AIja2026-04-12T23:08:58-07:00TP53 異常は CD19-CAR T細胞療法を受けた再発/難治性 B-ALL 患児および若年成人患者の重要な予後不良因子として現れる https://news.medxy.ai/vi/tp53-variants-cd19-car-t-cell-therapy/Medxy AIvi2026-04-12T23:06:16-07:00Các biến đổi TP53 xuất hiện là yếu tố dự báo bất lợi quan trọng trong điều trị liệu pháp tế bào T CAR CD19 cho bệnh nhân nhi và người lớn trẻ tuổi mắc bệnh bạch cầu cấp tính dòng B tái phát/kháng thuốc https://news.medxy.ai/tp53-alterations-b-all-prognosis/Medxy AIen2026-04-12T23:01:57-07:00TP53 Alterations Emerge as Critical Adverse Prognostic Factor in Pediatric and Young Adult Patients Treated with CD19-CAR T-Cell Therapy for Relapsed/Refractory B-ALL https://news.medxy.ai/zh/transplant-before-cancer/Medxy AIzh2026-04-12T19:07:04-07:00在癌症发生前决定移植：RUNX1家族性血小板障碍的新框架 https://news.medxy.ai/ja/transplant-decisions-runx1-disorder/Medxy AIja2026-04-12T19:04:23-07:00癌発症前の移植の決定：RUNX1家系血小板障害の新しいフレームワーク https://news.medxy.ai/vi/navigate-implant-decisions/Medxy AIvi2026-04-12T19:01:10-07:00Điều hướng quyết định cấy ghép trước khi ung thư phát triển: Một khung mới cho rối loạn tiểu cầu gia đình RUNX1 https://news.medxy.ai/transplant-decision-framework/Medxy AIen2026-04-12T18:56:09-07:00Navigating the Decision to Transplant Before Cancer Develops: A New Framework for RUNX1 Familial Platelet Disorder https://news.medxy.ai/zh/gprc5d-loss-myeloma-progression/Medxy AIzh2026-04-12T13:09:11-07:00当靶向治疗成为双刃剑：GPRC5D丢失如何促进多发性骨髓瘤进展 https://news.medxy.ai/ja/targeting-gprc5d-myeloma/Medxy AIja2026-04-12T13:07:48-07:00標的化が二面性を持つとき：GPRC5Dの喪失が多発性骨髄腫の進行を促進するメカニズム https://news.medxy.ai/vi/gprc5d-loss-leukemia/Medxy AIvi2026-04-12T13:05:27-07:00Khi Định Hướng Trở Thành Lưỡi Đao Hai Lưỡi: Sự Mất GPRC5D Có Thể Kích Thích Tiến Trình Bệnh Bạch Cầu Đa Hình https://news.medxy.ai/targeting-and-multiple-myeloma/Medxy AIen2026-04-12T13:01:55-07:00When Targeting Becomes a Double-Edged Sword: How Loss of GPRC5D May Fuel Multiple Myeloma Progression